ArticleImmunity, inflammation and disease2026
Effect of Respiratory Syncytial Virus on the Global Burden of Lower Respiratory Infections: Lessons From the Global Burden of Disease Study 1990-2021.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of Respiratory Syncytial Virus on the Global Burden of Lower Respiratory Infections: Lessons From the Global Burden of Disease Study 1990-2021.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) is a major cause of lower respiratory infections (LRIs), especially in children, the elderly, and immunocompromised individuals.
methodsUsing GBD 1990-2021 data, we analyzed global RSV-related LRI deaths and DALYs. Trends were assessed via age-standardized rates and joinpoint regression. We also examined regional and demographic disparities and their association with the Sociodemographic Index (SDI).
resultsIn 2021, RSV-related LRIs caused 31,525.1 deaths and 2.59 million DALYs globally, marking a 78.9% decrease since 1990. The greatest decline occurred between 2020 and 2021. South Asia and Sub-Saharan Africa showed the highest burden. Children under 5 and the elderly (80+) were most affected, particularly males. A negative correlation was observed between SDI and disease burden.
conclusionsRSV burden has declined, but remains high in low-SDI regions. Sustained public health efforts and vaccination are critical to further reduce impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.